1420 related articles for article (PubMed ID: 32034960)
1. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Rocha C; Beltran J; Song Y; Posso M; Solà I; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1043-1057. PubMed ID: 32064642
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma.
Agache I; Song Y; Rocha C; Beltran J; Posso M; Steiner C; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1058-1068. PubMed ID: 32154939
[TBL] [Abstract][Full Text] [Related]
6. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines.
Agache I; Song Y; Alonso-Coello P; Vogel Y; Rocha C; Solà I; Santero M; Akdis CA; Akdis M; Canonica GW; Chivato T; Del Giacco S; Eiwegger T; Fokkens W; Georgalas C; Gevaert P; Hopkins C; Klimek L; Lund V; Naclerio R; O'Mahony L; Palkonen S; Pfaar O; Schwarze J; Soyka MB; Wang Y; Zhang L; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2021 Aug; 76(8):2337-2353. PubMed ID: 33683704
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia.
Ali A; García E; Torres-Duque CA; Rey D; Botero L; Saenz S; Avila MP; Mazo E; Londoño S
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):361-374. PubMed ID: 37994432
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
Koski RR; Grzegorczyk KM
J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
12. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Akenroye A; Lassiter G; Jackson JW; Keet C; Segal J; Alexander GC; Hong H
J Allergy Clin Immunol; 2022 Nov; 150(5):1097-1105.e12. PubMed ID: 35772597
[TBL] [Abstract][Full Text] [Related]
14. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines.
Agache I; Song Y; Posso M; Alonso-Coello P; Rocha C; Solà I; Beltran J; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong PY; O'Mahony L; Schwarze J; Werfel T; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2021 Jan; 76(1):45-58. PubMed ID: 32691892
[TBL] [Abstract][Full Text] [Related]
16. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
[TBL] [Abstract][Full Text] [Related]
18. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
